Look­ing to rein­vent those trou­bled AAVs you've been read­ing about, in­vestors back a $110M re­boot ef­fort

Next week, Affinia Ther­a­peu­tics will present four new ab­stracts at the Amer­i­can So­ci­ety of Gene and Cell Ther­a­py. Though they bear ob­scure and aca­d­e­m­ic names …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER